JOSE JAYME GALVAO DE LIMA

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Revista / Livro: American Journal of Transplantation ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • conferenceObject
    Prognostic Value of Serum Uric Acid in Patients on the Waiting List for Renal Transplantation
    (2012) MUELA, H. C. S.; LIMA, J. J. G. De
    Background: High serum uric acid is associated with increased cardiovascular risk in the general population. Although hyperuricemia is common in patients with chronic kidney disease (CKD), the impact of uric acid on mortality and CV events remains unclear. Objective: We assessed the relationship between base-line serum uric acid and the risk of cardiovascular events and all-cause mortality in a group of patients on the waiting list for renal transplantation before and after renal transplantation. Methods: This was a longitudinal observational study conducted in 1020 hemodialysis patients (54±11 years old, 70% Caucasians, 59% males, 40% diabetics, 38% with CVD, median follow-up 26 months) on the waiting list assessed for cardiovascular risk from July 1999 to June 2011. Data collection was terminated either at the end of the study period or in the moment that the patient had a cardiovascular event or expired. Survival curves were compared by Kaplan-Meier method. 199 patients underwent renal transplantation (50±11 years old, 72% Caucasians, 55% males, 34% diabetics, 26% with associated CVD, median follow-up 19 months). Results: High base-line serum uric acid (≥7.2 mg/dL) was not associated with either CV events (myocardial infarction, stroke, heart failure, sudden death, unstable angina, acute arterial syndrome) or with all-cause mortality. Similar results were observed in subgroups of patients with diabetes, elevated C-reactive protein or associated CV disease. For patients who underwent renal transplantation post-transplant base-line uric acid ≥7.2 mg/dL was associated with increased probability of CV events (p=0.03, HR 1.6, 95% CI 1.03-2,54). Conclusion: Elevated serum uric acid was not predictor of cardiovascular events or death in patients on the waiting list for transplant. However, an increased post-transplant base-line uric acid was related to higher probability of CV events.
  • conferenceObject
    Cardioprotective Drugs and Acute Coronary Syndrome in Patients on the Waiting List for Renal Transplantation
    (2012) LIMA, J. J. G. De; GOWDAK, L. H. W.; PAULA, F. J. de; CESAR, L. A. M.; BORTOLOTTO, L. A.
    Background: The incidence of Acute Coronary Syndrome (ACS) in patients (pts) with advanced CKD is close to 30/1000 pts-year (Kidney Int 2002; 62: 1799). The effect of cardioprotective medications on the incidence of ACS on the waiting-list pts is poorly understood. Objective : to assess the incidence and risk factors for ACS in a cohort of 1522 hemodialysis pts on the waiting list for renal transplantation prospectively treated with aspirin, b-blockers, statins and renin-angiotensin inhibitors irrespectively of risk strati fi cation starting on inception and maintained before and after transplantation. Results: 83 pts (57±8 yo, 65% males, 65% Caucasians, 53% diabetics and 49% with associated CV disease) developed ACS (5.4/1000 pts-year): myocardial infarction (MI) = 53 (66%) and unstable angina (UA) = 28 (34%). The median time for the occurrence of ACS was 52 months. Compared to pts who did not develop CV events, ACS pts were older and had more angina, diabetes, associated CV disease, higher serum total-cholesterol, LV mass index and abnormal myocardial scan. The sole independent predictor of ACS was an altered myocardial scan (p=0.0009, 95% CI 0.21-0.80, HR 0.50). 35 out of 53 pts with MI (66%) died during hospitalization; UA was not associated with in-hospital deaths. Mortality was higher in pts with ACS compared to controls (55% versus 20%, p=0.0001, HR 0.28, 95% CI 0.20- 0.39). 8 pts with ACS underwent renal transplantation. There were 2 deaths caused by MI 1.6 and 12 months after operation. In the control group (n= 360) there were 4 MI-related deaths. Overall post-transplant mortality was comparable in ACS and in controls (p=0.29). Conclusions: the incidence of ACS appears to be reduced in this cohort prospectively treated with cardioprotective medications. Risk factors do not differ from those in the general population. Myocardial scan is useful to detect pts at higher risk of ACS. The incidence of ACS was not increased by renal transplantation in pts with previous ACS. The in-hospital mortality by MI is very high.